Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
Japan’s Big 4 Drug Wholesalers Log 17.6% Operating Profit Growth
Four major Japanese pharma wholesalers saw a rise in their combined sales and operating profit in the April-September period of 2024, driven by high-margin medicines and boosted efficiency in their distribution operations. According to a Jiho tally, sales recorded in…
To read the full story
Related Article
- Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
November 18, 2025
- Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
- Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
- Change in Dynamics? Suzuken Emerges as No. 2 among Big 4 Japan Wholesalers
November 15, 2023
- Top 4 Wholesalers on Solid Note with 30% Operating Profit Rise in FY2022
May 19, 2023
- Top 4 Wholesalers on Recovery Trend, Operating Profit Up 69.1% in April-September
November 16, 2022
BUSINESS
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
- Meiji Pharma Takes Stake in Lyric Bio to Back Next-Gen IVIg Manufacturing
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…